Log in to save to my catalogue

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2331832278

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

About this item

Full title

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2020-01, Vol.382 (1), p.41-50

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Osimertinib was compared with standard EGFR blockers among patients with non–small-cell lung cancer with activating mutations in
EGFR
. The median overall survival was 38.6 months with osimertinib and 31.8 months with erlotinib or gefitinib. This 20% lower risk of death was noted despite the crossover of patients from standard therapy to osim...

Alternative Titles

Full title

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2331832278

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2331832278

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1913662

How to access this item